Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer.

MLA

Westin, Shannon N., et al. “Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 27, no. 23, Dec. 2021, pp. 6354–65. EBSCOhost, https://doi.org/10.1158/1078-0432.CCR-21-1656.

APA

Westin, S. N., Labrie, M., Litton, J. K., Blucher, A., Fang, Y., Vellano, C. P., Marszalek, J. R., Feng, N., Ma, X., Creason, A., Fellman, B., Yuan, Y., Lee, S., Kim, T.-B., Liu, J., Chelariu-Raicu, A., Chen, T. H., Kabil, N., Soliman, P. T., … Mills, G. B. (2021). Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 27(23), 6354–6365. https://doi.org/10.1158/1078-0432.CCR-21-1656

Chicago

Westin, Shannon N, Marilyne Labrie, Jennifer K Litton, Aurora Blucher, Yong Fang, Christopher P Vellano, Joseph R Marszalek, et al. 2021. “Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 27 (23): 6354–65. doi:10.1158/1078-0432.CCR-21-1656.